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Background: Doubts remain about atherosclerotic disease and risk stratification of asymptomatic type-2 diabetic
patients (T2DP). This study aims to evaluate the usefulness of calcium score (CS) and coronary computed tomography
(CT) angiography (CTA) to predict fatal and non fatal cardiovascular events (CVEV) in T2DP.
Methods: Eighty-five consecutive T2DP undergoing CT (Phillips Brilliance, 16-slice) with CS and CTA were prospectively
enrolled in a transversal case-control study. Patients were followed for 48 months (range 18 - 68) to assess CVEV:
cardiovascular death, acute coronary syndrome, revascularisation and stroke. Potential predictors of CVEV were
identified. Predictive models based on clinical features, CTA and CS were created and compared.
Results: Performing CT impacted T2DP treatment. Cardiovascular risk was lowered during follow-up but metabolic
control remained suboptimal. CVEV occurred in 11.8% T2DP (3.1%/year). CS ≥86.6 was predictor of CVEV over time,
with a high negative predictive value, an 80% sensitivity and 74.7% specificity. Although its prognostic value was
not independent of the presence/absence of obstructive CAD, adding CS and CTA data to clinical parameters improved
the prediction of CVEV: the combined model had the highest AUC (0.888, 95%CI 0.789-0.987, p < 0.001) for the prediction
of the study endpoints.
Conclusions: CS showed great value in T2DP risk stratification and its prognostic value was further enhanced by CTA
data. Information provided by CT may help predict CVEV in T2DP and potentially improve their outcome.
Keywords: Cardiac computed tomography, Coronary artery calcium, Coronary CT angiography, Cardiovascular risk,
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Coronary artery disease (CAD) is a leading cause of mor-
bidity and mortality in patients with diabetes mellitus
[1,2]. Diabetics have more prevalent, extensive and cal-
cified coronary atherosclerosis than non-diabetics, with an
accelerated progression and higher prevalence of multi-
vessel disease [3-5]. Type-2 diabetics have also a higher
prevalence (26-36%) of silent atherosclerotic lesions and
asymptomatic ischemia, making the diagnosis of CAD
easier to miss and allowing the disease to progress to an
advanced stage before becoming clinically evident [5-10].* Correspondence: anacatarina.faustino@gmail.com
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reproduction in any medium, provided the orDiabetes has been considered a CAD risk equivalent and
secondary prevention strategies with antiplatelet therapy
and statins have been previously recommended [5,6,11].
However, the Guidelines of the European Society of Cardi-
ology on cardiovascular disease prevention (2012) no longer
recommend antiplatelet therapy with aspirin for diabetics
without clinical evidence of atherosclerotic disease, due
to higher risk of bleeding [12]. There is a wide variation
in the risk of cardiovascular events among asymptom-
atic diabetic patients: while some individuals without
coronary plaques are at relative low risk, deriving no
benefit from an aggressive therapy, others are high risk
individuals who may benefit from more intensive risk
modification or even revascularisation [5,12]. Timely
detection of silent CAD at an early stage of progressionl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lead to tailored treatment.
Cardiac computed tomography (CT) has been used to
detect CAD at an early stage [6]. Coronary artery calcium
score (CS) is a marker of atherosclerosis used to predict
the likelihood of significant CAD and myocardial ischae-
mia, with low radiation exposure and no need of contrast
agent. However, it can miss non-calcified CAD [5,13].
Coronary CT angiography (CTA) allows noninvasive
visualization of the coronary lumen and wall, detecting
both calcified and non-calcified plaque components. It re-
quires contrast agent and exposes patients to higher radi-
ation than CS.
Previous studies have failed to prove the usefulness of
CTA or functional tests in screening asymptomatic dia-
betics [5,7,8,14]. No study to date has demonstrated add-
itional value of CS and CTA when associated to clinical
variables and classic risk scores, such as Framingham.
This study aims to assess the additional benefit of CS and
CTA, when added to clinical risk stratification schemes, to




Case-control study enrolling asymptomatic diabetic pa-
tients referred for CT from our outpatient clinic. CS and
CTA were performed. Clinical and laboratory data were
collected from electronic registries concerning both
ICD-10 diagnostics and outpatient clinic follow-up. This
study was approved by our Institution´s Cardiology De-
partment Supervisor and Ethics Committee. All patients
provided informed consent before undergoing CT and
authorized the use of follow-up information.
Patients and eligibility criteria
A total of 85 consecutive type-2 diabetic patients, without
history of chest pain or dyspnoea were referred from our
hospital’s diabetes outpatient clinic for cardiovascular risk
assessment by CT between March 1, 2006, and April 30,
2009. Patients over 18 years old were included in the
study. Diabetes was diagnosed according to the American
Diabetes Association criteria [15] and patients were
on standard anti-diabetic therapy (diet, tablets and/or in-
sulin). Exclusion criteria were any evidence of stroke, ca-
rotid disease or peripheral artery disease, other known
cardiac diseases, contraindication to iodine-based contrast
agents, glomerular filtration rate (GFR) <30mL/min, preg-
nancy, inability to sustain a 15-second breath-hold, car-
diac arrhythmias or uninterpretable CTA.
Initial data collection
Patients were evaluated during an outpatient visit before
undergoing CT. Demographics, clinical data, duration ofdiabetes, neuropathy, retinopathy, nephropathy, cardio-
vascular risk factors (hypertension, dyslipidemia, smoking,
family history of premature CAD), metabolic syndrome
(defined according to ATPIII [16]), body weight, height,
waist circumference and blood pressure were evaluated.
Laboratorial tests included total cholesterol, triglycerides,
high density lipoprotein cholesterol, low density lipopro-
tein cholesterol, hemoglobin A1c, serum creatinine, C-
reactive protein and microalbuminuria. Body mass index,
GFR (MDRD formula) and Framingham risk score [17]
were calculated. Hypertension and dyslipidemia were de-
fined by a self-reported history or use of specific therapy.
CT data acquisition
All examinations were performed with a 16-slice CT scan-
ner (Brilliance 16; Philips Medical Systems©, Eindhoven,
the Netherlands). A prospective scan without contrast en-
hancement was performed to measure CS (sequential scan
with 8 × 3mm collimation, tube current 55mAs at 120kV,
3mm width), followed by 16-slice contrast-enhanced spiral
scan of the heart performed with ECG gating and retro-
spective post processing. CTA parameters: 16 × 0.75mm
collimation, 400ms gantry rotation, pitch of 0.298, tube
voltage at 120kV, maximum current of 600—800 mAs de-
pending on patient size, half-scan reconstruction mode
and imaging craniocaudal direction. All patients received
5mg of sublingual isosorbide dinitrate 5 minutes before
CTA acquisition. Patients with a heart rate >65bpm re-
ceived 50-200mg of oral metoprolol. A bolus of iodinated
contrast agent (370mOsm) was intravenously injected (4-
5.5 ml/s). A region of interest was placed in the descend-
ing thoracic aorta and image acquisition was automatically
initiated using bolus tracking (selected threshold: 110
Hounsfield units [HU]). Images were reconstructed in five
phases of the cardiac cycle (0, 37.5, 62.5, 75 and 87.5% of
the R-R interval) to minimize motion artifacts. The aver-
age radiation dose was 14mSv.
CT Image interpretation
CT image evaluation was performed on a separate 3D
workstation (Brilliance workstation, Philips Medical Sys-
tems, Eindhoven, the Netherlands) by two experienced
reviewers. CS was measured using the automatic calcium
detection algorithm of the workstation, according to
Agatston method, with a calcium threshold of 130 HU.
CTA were analysed by assessment of axial slices, multi-
planar reformations (along the vessel axis and cross-
sectional images), and the three thin-slab maximum
intensity projections. The coronary artery tree was di-
vided into proximal, medial and distal, according to clas-
sic angiographic definition. Plaques were classified as
obstructive or non-obstructive using a 50% threshold of
luminal narrowing. The presence of obstructive coronary
artery disease (CAD: > 50% lumen narrowing) in one
Table 1 Study population baseline characteristics
Patient characteristics n (%) Patient characteristics Mean ± sd
Male 42 (49.4%) Age (years) 60 ± 10
Caucasian 85 (100%) Body mass index (Kg/m2) 30.9 ± 4.5
Current smoker 8 (9.4%) Waist circunference (cm) 104.4 ± 9.2
Ex-smoker 17 (20%) Duration of diabetes (years) 13 ± 9
Metabolic syndrome 59 (69.4%) HbA1c (%) 8.2 ± 1.7
Hypertension 79 (92.9%) Serum creatinine (μmol/L) 69 ± 16.7
Dyslipidemia 68 (80%) GFR (mL/min/1.73m2) 98.9 ± 25.7
Family history of CAD 8 (9.4) Urine microalbumin (mg/24h) 61.4 ± 132.4
Insulin treatment 42 (49.4%) Total cholesterol (mmol/L) 5 ± 1.3
Oral hypoglycaemic therapy 73 (85.9%) LDL cholesterol (mmol/L) 3.1 ± 1
Statins 45 (52.9%) HDL cholesterol (mmol/L) 1.2 ± 0.4
ACE inhibitor/ARB 31 (36.1%) Triglycerides (mmol/L) 1.9 ± 1.3
Antiplatelets 69 (81.2%) C-reactive protein (mg/dL) 0.38 ± 0.35
Diabetic neuropathy 19 (24.1%) Framingham 21 ± 12
Diabetic retinopathy/nephopaty 30 (38%)
Legend: CAD, coronary artery disease; ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; GFR, Glomerular filtration rate.
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(multivessel disease) was evaluated. Plaques were de-
fined as structures >1mm2 within and/or adjacent to the
vessel lumen, distinct from lumen and surrounding tis-
sue. Plaques were classified as: calcified – if they had
more than 50% calcified tissue (density >130HU in native
scans), mixed – if composed with <50% calcium, and non-
calcified lesions - without any calcium. After independentTable 2 Results of cardiac computed tomography
evaluation
Cardiac computed tomography Results
Calcium score, mean ± sd 137 ± 250
Calcium score > 400, n (%) 8 (9.4%)
Calcium score = 0, n (%) 33 (38.8%)
Coronary angiography
Atherosclerotic plaques, n(%) 57 (67.1%)
Non-calcified, n (%) 12 (14.1%)
Mixed, n (%) 19 (22.4%)
Calcified, n (%) 52 (61.2%)
Calcium score = 0, n (%) 5 (5.8%)
Obstructive plaques, n (%) 21 (24.7%)
Non-calcified, n (%) 4 (4.7%)
Mixed, n (%) 8 (9.4%)
Calcified, n (%) 10 (11.8%)
Calcium score = 0, n (%) 1 (1.2%)
Single-vessel disease 14 (16.5%)
Multivessel disease 7 (8.2%)evaluations, the final diagnosis was obtained by a consen-
sus interpretation of the two reviewers.
Study endpoints
The primary outcome of this study was a combined end-
point of fatal and non-fatal cardiovascular events, includ-
ing: cardiovascular death (due to cardiovascular causes,
obtained according to the death certificate diagnosis),
non-fatal acute myocardial infarction (determined from
review of hospital case notes and diagnosed according to
the Universal Definition of Myocardial Infarction [18]),
unstable angina (clinical features of an acute coronary syn-
drome without diagnostic enzyme changes), revascularisa-
tion (excluding that performed immediately after CT),
stroke (rapid onset of focal or global neurological deficit
lasting ≥24h or leading to death, with clinical findings sup-
plemented by neurological imaging).
Patient follow-up
Following the CT, patients were followed at the diabetes
outpatient clinic according to routine clinical practice.
Follow-up was performed between October 1, 2010, and
November 30, 2011. Data were obtained by review of cli-
nical and laboratorial records from our hospital’s diabetes
outpatient clinic, hospital ward and emergency depart-
ment admission(s). For patients who were not routinely
followed at our institution, an extra follow-up appoint-
ment was performed in November 2011.
Statistical analysis
Statistical analysis was performed using SPSS, version 17.0.
Baseline characteristics were described with mean ±
Table 3 Therapeutic improvement observed after cardiac computed tomography results
Therapeutic approach Before CT After CT Improvement p
Percutaneous revascularisation, n (%) 0 6 (7.1%) 6 (7.1%) _____
Medical therapy, n (%) 22 (25.9%) _____
Antiplatelets 31 (36.1%) 42 (49.4%) +12.9% ns
Statins 45 (52.9%) 58 (68.2%) +15.3% 0.041
ACE inhibitor/ARB 69 (81.2%) 73 (85.9%) +4.7% ns
Oral hypoglycaemic agents 73 (85.9%) 74 (87.1%) +1.2% ns
Insulin therapy 42 (49.4%) 43 (50.6%) +1.2% ns
Legend: ACE, angiotensin-converting-enzyme; ARB, angiotensin receptor blocker; p, significance level.
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portions for categorical data. Continuous variables of time
were also described with median, minimum and maximum
value. The Kolmogorov-Smirnov test was used to test the
normal distribution of continuous variables. The Chi-
square test, Student’s t-test and non-parametric equivalent
tests were used when appropriate. Regression estimation
techniques were applied to replace missing values whenever
the number of missing values was negligible, otherwise
cases with missing values would be omitted. P values <0.05
(two-sided) were considered statistically significant.
A comparative analysis of diabetics with and without
cardiovascular events was performed to evaluate potential
predictors. Univariate analysis was performed to evaluate
a potential association with the study endpoints. Cox re-
gression (method Forward Conditional) was performed to
identify the independent predictors of cardiovascular
events over time. Treatment started after CT (revasculari-
sation, antiplatelet agents, statins) and duration of diabetes
were also regarded.
The discriminatory power of cardiovascular events
predictors was then evaluated through the receiver oper-
ating characteristic (ROC) curve, which refers to the
ability of a model to assign a higher probability to pa-
tients reaching the study endpoint than those who didTable 4 Risk factors and risk profile by the time of CT (before
Risk profile
Framingham, mean ± sd
Systolic blood pressure (mmHg), mean ± sd
Total cholesterol (mmol/L), mean ± sd
LDL cholesterol (mmol/L), mean ± sd
HDL cholesterol (mmol/L), mean ± sd
Triglycerides (mmol/L), mean ± sd
Hemoglobin A1c (%), mean ± sd
Microalbuminuria (mg/24h), mean ± sd
Glomerular filtration rate (mL/min/1,73m2), mean ± sd
Waist circunference (cm), mean ± sd
Current smoking, n (%)
Legend: p – significance level.not reach it. Potential predictors presented as continu-
ous variables were converted into binary variables using
as cutoff point the Youden index, which is the point on
the ROC curve where optimal sensitivity and specificity
are achieved.
Predictor models were created trough multivariate ana-
lysis (binary logistic regression with the method Enter)
using events predictors (as continuous variables whenever
possible): Clinical model, comprising GFR, age and Fra-
mingham evaluated before CT; CT model, comprising
CS, obstructive CAD and atherosclerotic plaques; Clin-
ical-CS model, including CS and parameters included in
Clinical model; and a Combined model, composed of pa-
rameters included in both Clinical and CT models. The
regression coefficients obtained were then applied to cal-
culate predicted risks according to predictor models.
Finally, comparisons of areas under ROC curves (AUC)
were performed between predictor models and cardiovas-
cular events predictors using MedCalc for Windows ver-
sion 9.2.0.1.
Results
Study population and CT results
Eighty-five patients were referred for CT. Demographic,
clinical and laboratorial characteristics of study population) and at time of follow-up (after)
At CT At follow-up p
21.0 ± 11.6 20.8 ± 9.60 ns
158 ± 18 145 ± 21 <0.001
4.5 ± 1.3 4.4 ± 1.1 ns
2.7 ± 1.1 2.4 ± 0.9 ns
0.7 ± 0.5 0.8 ± 0.4 ns
1.4 ± 1.3 1.2 ± 0.4 ns
7.8 ± 1.7 7.2 ± 1.5 0.049
61.2 ± 132.4 41.8 ± 97.5 ns
98.4 ± 25.7 80 ± 26.1 <0.001
104 ± 9 106 ± 10 ns
8 (9.4%) 5 (5.9%) ns
Table 5 Events occurred during follow-up
Follow-up: 45 ± 13 months n (%)
Cardiovascular events (CVEV) 10 (11.8%)
Type of CVEV
Acute coronary syndrome 1 (1.2%)
Stroke 7 (8.2%)
Cardiovascular death 2 (2.4%)
All-cause mortality, n (%) 3 (3.5%)
Cardiovascular death 2 (2.4%)
Non-cardiovascular death 1 (1.2%)
CVEV and CS = 0, n (%) 0 (0%)
CVEV and CS < 400, (%) 7 (8.2%)
CVEV and CS ≥ 400, n (%) 3 (3.5%)
Table 6 Cardiovascular risk factors, markers of diabetes sever




Increased waist circunference, CT (%)
Metabolic syndrome, CT (%)
Duration of diabetes, CT (years, mean ± sd)
Diabetic neuropathy, CT (%)
Diabetic retinopathy/nephropathy, CT (%)
Hemoglobin A1c, CT (%, mean ± sd)
Microalbuminuria, CT (mg/24h, mean ± sd)
Serum C-reactive protein, CT (mg/dL, mean ± sd)
Percutaneous revascularization, CT (%)
Antiplatelets, CT (%)
Statins, CT (%)
ACE inhibitor/ARB, CT (%)
Oral hypoglycaemic therapy, CT (%)
Insulin therapy, CT (%)
Hemoglobin A1c, Fup (%, mean ± sd)
Microalbuminuria, Fup (mg/24h, mean ± sd)
Serum C-reactive protein, Fup (mg/24h, mean ± sd)
Antiplatelets, Fup (%)
Statins, Fup (%)
ACE inhibitor/ARB, Fup (%)
Oral hypoglycaemic therapy, Fup (%)
Insulin therapy, Fup (%)
Duration of follow-up (months, mean ± sd)
Legend: CT – evaluated when computed tomography was performed; for therapeu
follow-up; p- significance level; ACE - angiotensin-converting-enzyme; ARB - angiote
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dian duration of diabetes after diagnosis was 10 years
(range 1 - 38 years).
In our population the median CS was 34 (range 0 -
1293), and a CS > 400 was seen in 9% of the patients.
The absence of coronary calcification (CS = 0) was noted
in 39% of the patients (Table 2).
By CTA, coronary atherosclerotic plaques were found in
67.1% patients and were obstructive in 23.8%. Five patients
(5.8%) with a CS of zero had non-calcified plaques, of
which one (1.2%) was obstructive (Table 2). Coronary athe-
rosclerosis was completely absent in 32.9% of patients.
Follow-up: impact of CT results on treatment and
cardiovascular risk profile
Subsequent to CT results, 7.1% of patients underwent
percutaneous revascularisation. Medical therapy was opti-
mised in 25.9% patients: 4.7% started ACE inhibitors/
ARB´s, 12.9% were put on antiplatelet therapy, and 15.3%ity, therapeutics and duration of follow-up for patients





16 ± 8 13 ± 9 ns
44.4 21.4 ns
33.3 38.6 ns
7.6 ± 1.3 8.3 ± 1.8 ns
171.9 ± 291.4 45.1 ± 122.6 ns







7.7 ± 1.5 7.6 ± 1.6 ns
39.3 ± 46.8 39.9 ± 118.4 ns






45.7 ± 15.6 45.2 ± 13.0 ns
tics, it includes changes performed following CT; Fup – evaluated at time of
nsin receptor blocker.
Table 7 Predictors of cardiovascular events by univariate analysis
Predictors of CVEV: univariate analysis OR 95% CI p
Age >66 years 8.604 1.996 - 37.086 0.001
GFR <99.2 mL/min/1.73m2 9.750 1.176 - 80.829 0.012
Framingham >22 4.667 1.111 – 19.602 0.025
Calcium score >86,6 11.789 2.299 – 60.445 <0.001
Atherosclerotic plaques 1.210 1.076 – 1.367 0.018
Calcium score ≥400 6.000 1.177- 30.581 0.018
Obstructive coronary artery disease 6.000 1.501 – 23.991 0.018
Multivessel disease (stenosis) ———— ———— ns
Female gender 0.207 0.041-1.042 0.039
Odds ratio (OR) and 95% confidence intervals (CI) and the significance level (p) are shown.
Legend: GFR - Glomerular Filtration Rate.
Presented parameters are related to initial assessment and data obtained by Computed tomography.
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(p = 0.041). Treatment with an antiplatelet agent, a statin
or percutaneous revascularisation was started in 17.6% of
patients following CT, which was also a significant change
(p = 0.013), and none of these treatments were discontin-
ued. Antidiabetic therapy was intensified in 2.4% of pa-
tients (Table 3). Information regarding the cardiovascular
risk profile by the time of CT and at time of follow-up is
given in Table 4.
Follow-up: study endpoints
A median clinical follow-up of 48 months (range 18 - 68)
was performed. During this period, 10 cardiovascular events
(11.8%) were reported: one unstable angina (1.2%), seven
strokes (8.2%) and two cardiovascular deaths (2.4%) – Table 5.
No events were observed in patients with zero CS (0% vs.
19.2%, p = 0.007) or without atherosclerotic plaques (0%
vs. 17.5%, p = 0.018), both presenting a negative predictive
value of 100%. Seven events (in 9.1% of patients) occurred
in patients with CS < 400, and three (8.2%) were reported
in patients with CS ≥ 400 (Table 5).
Length of follow-up was not different between patients
with and without cardiovascular events (Table 6).
On univariate analysis, none of the cardiovascular risk
factors, markers of diabetes severity or therapeutics pre-
sented in Table 6 were predictors of cardiovascular events.
In this analysis, predictors of events were age >66 yearsTable 8 Predictors of cardiovascular events by Cox regression
Predictors of CVEV: Cox regression
Age —
Glomerular filtration rate
Absence of obstructive coronary artery disease
Calcium score —
Atherosclerotic plaques —
Presented parameters are related to initial assessment and data obtained by Comp
significance level (p) are shown.old, GFR <99.2mL/min/1.73m2 and Framingham >22
when CT was performed, CS > 86.6, atherosclerotic pla-
ques and obstructive CAD on CT, with the primary end-
point occurring in 28.6% patients with vs. 6.3% without
obstructive CAD. Treatment with antiplatelet agents, sta-
tins and/or revascularisation did not achieve statistical sig-
nificance. Multivessel disease was not associated with the
primary endpoint (Table 7). The cutoff points for age, CS,
GFR and Framingham were determined by Youden índex
on ROC curve analysis. The best threshold of CS to iden-
tify cardiovascular events was 86.6, with 80% sensitivity
(vs. 20% for CS ≤ 86.6, p < 0.001) and 74.7% specificity.
All the predictors of cardiovascular events on univa-
riate analysis were included on a Cox regression analysis.
GFR (HR 0.953, 95%CI: 0.920-0.988, p = 0.009) and
absence of obstructive CAD (HR 0,110, 95% CI: 0.027-
0.451, p = 0.002) were independently associated with car-
diovascular events over time, behaving as protectors
(Table 8). CS > 86.6 was an independent predictor of car-
diovascular events over time when considered separately
from obstructive CAD (OR 10.725, 95%CI: 2.255-51.018,
p = 0.003). Hazard function for primary endpoint along
time according to CS higher than 86.6 (vs. ≤86.6) and
obstructive CAD is presented in Figure 1.
Different prediction models were created based on
clinical and CT predictors of cardiovascular events.
ROC curve analysis for the isolated parameters andanalysis
OR 95% CI p
——— ———— ns
0.953 0.920 – 0.988 0.009
0.110 0.027 – 0.451 0.002
——— ———— ns
——— ———— ns
uted Tomography. Hazard ratio (HR) and 95% confidence intervals (CI) and the
Figure 1 Hazard function by Cox regression showing cardiovascular events along time according to Calcium score higher than 86.6
(vs ≤ 86.6), and the presence of obstructive coronary artery disease (CAD).
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Clinical parameters and calcium score showed good dis-
criminatory power for identifying cardiovascular events.
CS had the best AUC of all isolated parameters, while the
Combined model, composed of parameters included in
both Clinical and CT models, showed the highest discrim-
inatory power among predictor models.
In assessing cardiovascular events, the Combined model
was significantly better than GFR (difference between
AUC: 0.150, 95%CI 0.004-0.260, p = 0.008) and showed a
trend for a higher discriminatory power than Framingham
(difference between AUC: 0.184, p = 0.052), age (difference
between AUC: 0.135, p = 0.078 and the Clinical model
(difference between AUC: 0.065, p = 0.086). It did not per-
form significantly better than CS or the other predictor
models (Table 9).Figure 2 ROC curve of different parameters and models for
identifying patients with cardiovascular events. Legend:
1/GFR- reciprocal function of glomerular filtration rate (used only for
drawing the curve).Discussion
Our study suggests that CS can predict cardiovascular
events in asymptomatic diabetic patients with a high ef-
ficacy and its prognostic power can be further enhanced
by CTA results. To our knowledge, no study conducted
to date has assessed CTA results (presence of obstruct-
ive CAD and atherosclerosis) as predictors of cardiovas-
cular events in asymptomatic diabetics or its additional
value over calcium score for cardiovascular events pre-
diction in this population.
In this study, CS was an age-independent predictor of
cardiovascular events over time, and its diagnostic per-
formance was better than any isolated clinical parameter
(Figure 2, Table 9), cardiovascular risk factor or metabolic
control marker (Table 6). The best cutoff for predicting
cardiovascular events (86.6) identified 80% of patients
who suffered a cardiovascular event and was associated
with a risk of events 10.7 times higher over time. It was
lower than the value commonly used to predict high risk
of CAD in general population (400). A CS of 0, as a low
risk marker, missed one patient with significant CAD but
did not fail to exclude cardiovascular events, highlighting
its negative predictive value.
Evaluation of obstructive CAD and atherosclerosis by
CTA increased the CS discriminatory power for cardio-
vascular events, providing a CT model as accurate as the
clinical model. The association of CT and clinical model
was more efficient in the prediction of cardiovascular
events than GFR, Framingham, age and the Clinical
model. Although adding only CS to Clinical model en-
hanced its discriminatory ability, this difference was not
statistically significant for any single parameter, empha-
sizing the additional value of CTA over clinical model or
CS for predicting cardiovascular events.
In asymptomatic subjects from the general population
and without known CAD, CS has been shown to predict
cardiovascular events above and beyond traditional risk
factors [19-23]. However, the predictive value of CS in
Table 9 Receiver operating characteristic (ROC) curve evaluation for CVEV prediction
Prediction of CVEV: ROC analysis AUC 95% CI p
Framingham 0.704 0.506 – 0.902 0.037
Glomerular filtration rate 0.262 0.132 – 0.392 0.015
Age 0.753 0.596 – 0.911 0.010
Calcium score 0.808 0.690 – 0.926 0.002
Clinical model 0.823 0.692 – 0.953 0.001
Clinical-CS model 0.832 0.692 – 0.972 0.001
CT model 0.833 0.711 – 0.955 0.001
Combined model 0.888 0.789 – 0.987 <0.001
ROC comparisons - Combined model vs: AUC (difference) 95% CI p
Glomerular filtration rate 0.150 0.004-0.260 0.008
Framingham 0.184 −0.002-0.370 0.052
Age 0.135 −0.015-0.284 0.078
Calcium score 0.080 −0.022-0.182 0.123
Clinical model 0.065 −0.009-0.140 0.086
Clinical-CS model 0.056 −0.023-0.135 0.164
CT model 0.055 −0.025-0.135 0.180
Legend: Predictor models: CT model - composed by calcium score, obstructive Coronary Artery Disease and atherosclerotic plaques; Clinical model – composed by
clinical parameters evaluated before Computed Tomography: Glomerular Filtration Rate, age, Framingham; Clinical-CS model – composed by clinical parameters
and calcium score; Combined model – composed by parameters included in both clinical and CT models.
Areas under ROC curves (AUC), 95% confidence intervals (CI) and the significance level (p) are presented.
Results presented in this table are related to curves showed in Figure 2.
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large observational study including diabetic and non-
diabetic participants, CS predicted all cause mortality in
diabetics and added to the predictive power of the Fra-
mingham score, while diabetics with undetectable CS
had a mortality rate similar to that of non-diabetic individ-
uals [24]. In another study, CS was superior to established
risk factors in identifying silent myocardial ischaemia by
perfusion scintigraphy in type-2 diabetics [25]. The PRE-
DICT Study (Coronary calcium measurement improves
prediction of cardiovascular events in asymptomatic
patients with type 2 diabetes) [13] also documented CS
as a powerful predictor of cardiovascular events in asymp-
tomatic type-2 diabetics that can enhance prediction pro-
vided by established risk models. Our data were consistent
with those presented in these studies.
Functional tests have also been evaluated to screen
asymptomatic diabetics. DIAD (Cardiac Outcomes after
Screening for Asymptomatic Coronary Artery Disease in
Patients With Type 2 Diabetes) study [14] was a rando-
mised trial that evaluated the impact of ischaemia screen-
ing in the prevention of cardiovascular events. Authors
concluded that smaller ischaemic defects by adenosine-
stress radionuclide myocardial perfusion imaging in
asymptomatic diabetic patients were related to a lower
event rate. However, the positive predictive value of hav-
ing moderate or large perfusion defects was only 12%, the
total event rate was low (2.9% over a follow-up 0f 4.8years: 0.6/year) and there were no significant differences
between the screened and unscreened group.
Our study population had long diabetes duration and
high prevalence of cardiovascular risk factors such as
hypertension and dyslipidemia, and metabolic syndrome.
Their cardiovascular risk was very high according to Fra-
mingham risk score, used for prediction of fatal and
non-fatal cardiovascular events, and was reduced over
time, due in part to therapeutic improvement performed
taking into account CT results.
CTA revealed obstructive CAD in 24.7% of diabetics, a
prevalence similar to that reported in previous studies
[1,7]. Coronary atherosclerosis was completely absent in
32.9% and this was protective from cardiovascular events,
with a negative predictive value of 100%. These results
highlight the atherosclerotic heterogeneity of asymptom-
atic diabetic patients, which was essential to identify and
would not be possible without CT.
We found a high event rate (11.8% over 45 ± 13 months,
3.1% per year) in the study population. The addition of CS
and CTA data to clinical predictors improved the identifi-
cation of patients at risk of cardiovascular events, who
may benefit from early and potentially more aggressive
treatment with statins, antiplatelet agents and revasculari-
sation, as well as tight control of glucose levels.
However, in order to perform CT scan in all asymp-
tomatic diabetics, radiation has to be cut to the mini-
mum. New generation scanners and strategies of dose
Faustino et al. BMC Cardiovascular Disorders 2014, 14:2 Page 9 of 10
http://www.biomedcentral.com/1471-2261/14/2modulation may significantly reduce radiation exposure
to less than 1 mSV.
Limitations
We describe results of a single-center study, with a lim-
ited number of enrolled patients. This was due to a low
availability of CT when the study began, but also to the in-
clusion criteria, as this examination is not routinely per-
formed in asymptomatic individuals. Indeed, our outpatient
diabetes clinic receives patients at high cardiovascular risk
or with very poor metabolic control, most of which could
not be enrolled due to CAD history, ischemic symptoms or
low GFR. These data may therefore present a selection bias
that may not fit to general asymptomatic diabetic popula-
tion. A larger sample from other centers would be needed
for external validation of these results and of the Combined
model created.
Patients´ treatment did not follow a specific protocol, as
they were treated according to routine clinical practice of
different diabetologists.
We observed therapeutic changes immediately after
performing CT, however a control group would be re-
quired to evaluate the real impact of CT in cardiovascu-
lar events reduction.
Conclusion
Evaluating atherosclerosis and obstructive CAD through
the combination of CS and CTA showed high predictive
value for cardiovascular events in asymptomatic type-2
diabetic patients. Furthermore, the use of these two CT
methods on top of clinical data improved risk stratifica-
tion even further, identifying those who can derive the
most benefit from intensive prevention measures. The
recognition of atherosclerotic disease in this very hete-
rogeneous group of patients led to changes in the
therapeutic strategy. However, the true impact of CT
risk-stratification and the resulting therapeutic changes on
long-term prognosis still needs to be further assessed in
randomized controlled trials.
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